INSULIN Act of 2026

The INSULIN Act of 2026 mandates that group and individual health insurance plans cap out-of-pocket costs for selected insulin products at $35 per 30-day supply, effective for plan years beginning on or after January 1, 2028. This cost limit applies to a variety of insulin types and delivery devices, with the cap set at the lesser of $35 or 25 percent of the negotiated price net of concessions. The bill also prohibits insurers from imposing deductibles or prior authorization requirements for these covered products unless clinically justified for safety reasons. Additionally, the legislation directs the Department of Health and Human Services to fund a resource center and hotline to help uninsured individuals find affordable insulin assistance programs, while requiring the Government Accountability Office to study the demographics of uninsured insulin users. Finally, it creates an expedited review process for biosimilar insulin applications when the Secretary determines there is inadequate competition in the market.